tbuckley/cabot-search huggingface dataset:
Finite nucleos(t)ide-analogue therapy for functional cure in HBeAg-negative chronic hepatitis B: recent development in the paradigm shift
Authors: Yun-Fan Liaw, George Papatheodoridis
Journal: Hepatology (2024)

Long-term nucleos(t)ide analogue (Nuc) therapy in chronic hepatitis B (CHB) may lead to hepatitis B virus (HBV) suppression, alanine aminotransferase (ALT) normalization, improvement of histological lesions, and prevention of liver disease progression, but rarely achieve HBsAg loss, the hallmark of functional cure. HBeAg-negative CHB patients have often been recommended to continue Nuc therapy until HBsAg loss, which usually means indefinitely. However, long-term/life-long Nuc therapy is associated with increasing costs and concerns of adverse outcomes subsequent to poor adherence and/or self-cessation/loss-to-follow-up. Hence, 2012 Asian-Pacific guidelines recommended that HBeAg-negative CHB patients can stop Nuc therapy after ≥12 months of HBV DNA undetectability. Subsequent Asian and few European studies have found the strategy of finite Nuc therapy to be feasible and reasonably safe. In 2016-2017, stopping Nuc was also included as a conditional strategy for HBeAg-negative CHB patients in the American and European guidelines. Furthermore, progressively increasing HBsAg loss rates with prolongation of off-Nuc follow-up were documented, being higher in Caucasians and more apparent beyond years 4-5 in Asian patients. Recently, a large study in patients with HBV cirrhosis showed not only higher 10-year HBsAg loss rate (15.3 vs. 1.6%) but also ~50% lower 10-year hepatocellular carcinoma incidence (16.5 vs. 29.5%) and 60% lower liver-related mortality/transplantation rate (6.1 vs. 15.1%) after Nuc cessation, as compared with well-matched patients continuing Nuc therapy. Since novel drug development aiming for functional cure has not been satisfactory, the strategy of finite Nuc therapy in HBeAg-negative CHB seems to be the best realistic option for functional cure today.
Exchangeable copper for patients with Wilson disease at follow-up: rethinking normal ranges or changing methodology
Authors: Zoe Mariño, Clàudia Garcia-Solà, José Ríos, Ariadna Bono, Sonia García, Anna Miralpeix, Rocío Andreu, Cristina Aguado, Xavier Forns, Mercè Torra, Marina Berenguer
Journal: Hepatology (2024)

Determining suitable copper parameters for monitoring Wilson disease remains a topic of ongoing discussion. International recommendations currently rely on the combination of urinary copper excretion and non-specific liver markers when considering therapy and time elapsed since diagnosis. The emergence of exchangeable copper (CuEX) as a novel measurement reflecting the “ free copper pool ” held promise as a valuable target to ensure metabolic stability during follow-up, although validation of target ranges remain unknown. We aimed at evaluating CuEX quantification in repeated samples from 92 real-world WD patients during a 2-year period. Patients were classified as “stable” if diagnosis had been made more than one year before and were compliant to stable anti-copper drug and dose. Otherwise, patients were classified as “non-stable”. Two-hundred and thirteen CuEX samples were obtained per clinical practice. Overall, 57% of CuEX measurements fell below the reference “range of normality”, whereas only 34% were within and 9% were above normal levels. There was no association of CuEX levels with therapy, elapsed time from diagnosis or clinical stability, although most of the samples above normality corresponded to non-stable patients. Only 23.4% of the CuEX samples were aligned with data obtained from concomitant urinary copper excretion. Our findings suggest that CuEX is a suboptimal tool for assessing copper homeostasis when used alone and should be used with caution if no additional information is available. Normal reference intervals for WD-treated patients should be redefined, as most of CuEX quantifications fell in the lower range, with no sign of overtreatment in these patients.
Cardiovascular Considerations Before Cancer Therapy
Authors: Zahra Raisi-Estabragh, Alexandra C Murphy, Sivatharshini Ramalingam, Marielle Scherrer-Crosbie, Teresa Lopez-Fernandez, Kerry L Reynolds, Marianne Aznar, Amy E Lin, Peter Libby, Raul Cordoba, Christine Bredsen-Masley, Ashu Wechalekar, Jane Apperley, Richard K Cheng, Charlotte H Manisty
Journal: JACC CardioOncology (2024)
2024 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery
Authors: Annemarie Thompson, Kirsten E. Fleischmann, Nathaniel R. Smilowitz, Lisa de las Fuentes, Debabrata Mukherjee, Niti R. Aggarwal, Faraz S. Ahmad, Robert B. Allen, S. Elissa Altin, Andrew Auerbach, Jeffrey S. Berger, Benjamin Chow, Habib A. Dakik, Eric L. Eisenstein, Marie Gerhard-Herman, Kamrouz Ghadimi, Bessie Kachulis, Jacinthe Leclerc, Christopher S. Lee, Tracy E. Macaulay, Gail Mates, Geno J. Merli, Purvi Parwani, Jeanne E. Poole, Michael W. Rich, Kurt Ruetzler, Steven C. Stain, BobbieJean Sweitzer, Amy W. Talbot, Saraschandra Vallabhajosyula, John Whittle, Kim Allan Williams
Journal: Journal of the American College of Cardiology (2024)
Development of a staging system for hepatoid adenocarcinoma of the stomach based on multicenter data: A retrospective cohort study
Authors: Ying-Qi Huang, Ze-Ning Huang, Qing-Qi Hong, Peng Zhang, Zi-Zhen Zhang, Liang He, Liang Shang, Lin-Jun Wang, Ya-Feng Sun, Zhi-Xiong Li, Jun-Jie Liu, Fang-Hui Ding, En-De Lin, Yong-An Fu, Shuang-Ming Lin, Qi-Yue Chen, Chao-Hui Zheng, Chang-Ming Huang, Ping Li
Journal: International Journal of Surgery (2024)
Back pain Knowledge and beliefs Survey (BacKS): development and assessment of measurement properties
Authors: Leticia Amaral Corrêa, Mark Hancock, Stephanie Mathieson, Arianne Verhagen, Ben Darlow, Paul William Hodges, Simon French
Journal: British Journal of Sports Medicine (2024)

Objective To develop and evaluate a new patient-reported outcome measure (PROM) to assess people’s knowledge and beliefs about low back pain. Methods This study followed the COnsensus-based Standards for the selection of health Measurement INstruments guidelines. An 18-item preliminary version of the Back pain Knowledge and beliefs Survey (BacKS) was generated based on evidence-based key messages and current clinical guidelines for low back pain. Four items were added following input from three consumers and seven experts. Focus groups (n=9) confirmed content validity. The 22-item version was completed by 258 Australian-based adults (&gt;18 years) with self-reported low back pain. A follow-up survey was sent 1 week later. The following measurement properties were evaluated to produce, and then assess the final version of BacKS: structural validity (exploratory factor analysis); internal consistency (Cronbach’s alpha); test–retest reliability (intraclass correlation coefficient); measurement error (Smallest Detectable Change); construct validity (hypothesis tested: moderate positive Pearson correlation between BacKS and Back Beliefs Questionnaire); plus, interpretability and feasibility. Results The final BacKS comprised 20 items with a 2-factor structure (biomedical factor: 9 items, score ranging from 9 to 45, and self-care factor: 11 items, score ranging from 11 to 55). Internal consistency and reliability were adequate (&gt;0.70) for each factor. Smallest detectable change was 4.4 (biomedical factor) and 7.0 (self-care factor). Our construct validity hypothesis was confirmed (Pearson correlation=0.53). No floor or ceiling effects were detected. Conclusion The BacKS is a valid, reliable and feasible PROM to measure knowledge and beliefs about low back pain in clinical practice and research settings.
2024 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Authors: Annemarie Thompson, Kirsten E. Fleischmann, Nathaniel R. Smilowitz, Lisa de las Fuentes, Debabrata Mukherjee, Niti R. Aggarwal, Faraz S. Ahmad, Robert B. Allen, S. Elissa Altin, Andrew Auerbach, Jeffrey S. Berger, Benjamin Chow, Habib A. Dakik, Eric L. Eisenstein, Marie Gerhard-Herman, Kamrouz Ghadimi, Bessie Kachulis, Jacinthe Leclerc, Christopher S. Lee, Tracy E. Macaulay, Gail Mates, Geno J. Merli, Purvi Parwani, Jeanne E. Poole, Michael W. Rich, Kurt Ruetzler, Steven C. Stain, BobbieJean Sweitzer, Amy W. Talbot, Saraschandra Vallabhajosyula, John Whittle, Kim Allan Williams Sr.
Journal: Circulation (2024)

Aim: The “2024 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery” provides recommendations to guide clinicians in the perioperative cardiovascular evaluation and management of adult patients undergoing noncardiac surgery. Methods: A comprehensive literature search was conducted from August 2022 to March 2023 to identify clinical studies, reviews, and other evidence conducted on human subjects that were published in English from MEDLINE (through PubMed), EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. Structure: Recommendations from the “2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery” have been updated with new evidence consolidated to guide clinicians; clinicians should be advised this guideline supersedes the previously published 2014 guideline. In addition, evidence-based management strategies, including pharmacological therapies, perioperative monitoring, and devices, for cardiovascular disease and associated medical conditions, have been developed.
Sustained Benefit of Zanubrutinib vs Ibrutinib in Patients With R/R CLL/SLL: Final Comparative Analysis of ALPINE
Authors: Jennifer R. Brown, Barbara Eichhorst, Nicole Lamanna, Susan M. O’Brien, Constantine S. Tam, Lugui Qiu, Wojciech Jurczak, Keshu Zhou, Martin Šimkovič, Jiří Mayer, Amanda Gillespie-Twardy, Alessandra Ferrajoli, Peter S. Ganly, Robert Weinkove, Sebastian Grosicki, Andrzej Mital, Tadeusz Robak, Anders Osterborg, Habte A. Yimer, Megan Wang, Tommi Salmi, Liping Wang, Jessica Li, Kenneth Wu, Aileen Cohen, Mazyar Shadman
Journal: Blood (2024)
Extensive intraoperative peritoneal lavage with surgery, compared to surgery alone, for patients diagnosed with gastric cancer: A systematic review and meta-analysis of randomized controlled trials
Authors: Mariam Adil, Dua Ghori, Eman Anwar, Maryam Shaukat, Muhammad Tauseef Haider Malik, Dua Atif Murtaza, Khadija Awais Sumra, Rabia Essani, Urooj Nizami, Bakhtawer Nawaz Khan, Hunaina Abid, Malik Olatunde Oduoye
Journal: International Journal of Surgery (2024)
Recurrent CLTC::SYK fusions and CSF1R mutations in juvenile xanthogranuloma of soft tissue
Authors: Paul G Kemps, Hans J Baelde, Ruben Harmen Paul Vorderman, Ellen Stelloo, Joost F Swennenhuis, Karoly Szuhai, Meindert H Lamers, Boyd Kenkhuis, Maysa Al-Hussaini, Inge Briaire-de Bruijn, Suk Wai Lam, Judith V.M.G. Bovee, Arjen HG Cleven, Robert M. Verdijk, Carel J.M. van Noesel, Marijke van Dijk, Marijn A. Scheijde-Vermeulen, Annette H Bruggink, Jan AM van Laar, Andrica C.H. de Vries, Wim Tissing, Cor van den Bos, Andreas von Deimling, Tom van Wezel, Astrid G.S. van Halteren, Pancras C.W. Hogendoorn
Journal: Blood (2024)
Pretransplant MRD detection of fusion transcripts is strongly prognostic in KMT2A-rearranged acute myeloid leukemia
Authors: Sun Loo, Nicola Potter, Adam Ivey, Jenny O'Nions, Roderick Moon, Jelena Jovanovic, Chun Yew Fong, Natasha S Anstee, Ing S Tiong, Jad Othman, Chong Chyn Chua, Hannah Renshaw, Robert Baker, Shaun Fleming, Nigel H. Russell, David Ritchie, Ashish Bajel, Hsin-An Hou, Richard James Dillon, Andrew H. Wei
Journal: Blood (2024)
Disruption of cotranscriptional splicing suggests that RBM39 is a therapeutic target in acute lymphoblastic leukemia
Authors: Qi Jin, Ethan Harris, Jacquelyn A Myers, Rashid Mehmood, Anitria Cotton, Hazheen K Shirnekhi, David W Baggett, Jeremy Qiang Wen, Andrew B Schild, Rahul S Bhansali, Jonathon Klein, Shilpa Narina, Tim Pieters, Akihide. Yoshimi, Shondra M Pruett-Miller, Richard Kriwacki, Omar Abdel-Wahab, Sebastien Malinge, Panagiotis Ntziachristos, Esther A Obeng, John D. Crispino
Journal: Blood (2024)
Outcomes in patients with ETV6::RUNX1 or high-hyperdiploid B-ALL treated in the St. Jude Total Therapy XV/XVI studies
Authors: Katelyn Purvis, Yinmei Zhou, Seth E. Karol, Jeffrey E. Rubnitz, Raul C. Ribeiro, Shawn HR Lee, Jun J. Yang, W. Paul Bowman, Lu Wang, Stephanie B Dixon, Kathryn G Roberts, Qingsong Gao, Cheng Cheng, Charles G. Mullighan, Sima Jeha, Ching-Hon Pui, Hiroto Inaba
Journal: Blood (2024)
Metabolic reprogramming of hypoxic tumor-associated macrophages through CSF-1R targeting favors treatment efficiency in colorectal cancers
Authors: Khaldoun Gharzeddine, Cristina Gonzalez Prieto, Marie Malier, Clara Hennot, Renata Grespan, Yoshiki Yamaryo-Botté, Cyrille Y Botté, Fabienne Thomas, Marie-Hélène Laverriere, Edouard Girard, Gael Roth, Arnaud Millet
Journal: Journal for ImmunoTherapy of Cancer (2024)

Tumor-associated macrophages participate in the complex network of support that favors tumor growth. Among the various strategies that have been developed to target these cells, the blockade of the colony-stimulating factor 1 receptor (CSF-1R) receptor is one of the most promising ones. Here, we characterize the resulting state of human macrophages exposed to a CSF-1R kinase inhibitor. Using RNA sequencing and metabolomics approach, we characterize the reprogramming of human monocyte-derived macrophages under CSF-1R targeting. We find that CSF-1R receptor inhibition in human macrophages is able to impair cholesterol synthesis, fatty acid metabolism and hypoxia-driven expression of dihydropyrimidine dehydrogenase, an enzyme responsible for the 5-fluorouracil macrophage-mediated chemoresistance. We show that this inhibition of the CSF-1R receptor leads to a downregulation of the expression of sterol regulatory element-binding protein 2, a transcription factor that controls cholesterol and fatty acid synthesis. We also show that the inhibition of extracellular signal-regulated kinase 1/2 phosphorylation resulting from targeting the CSF-1R receptor destabilizes the expression of hypoxic induced factor 2 alpha in hypoxia resulting in the downregulation of dihydropyrimidine dehydrogenase expression restoring the sensitivity to 5-fluorouracil in colorectal cancer. These results reveal the unexpected metabolic rewiring resulting from the CSF-1R receptor targeting of human macrophages and its potential to reverse macrophage-mediated chemoresistance in colorectal tumors.
Neurofilament light chain levels as an early predictive biomarker of neurotoxicity after CAR T-cell therapy
Authors: Marion Larue, Amélie Bouvier, Alexis Maillard, Alexis Cuffel, Vincent Allain, Renata Ursu, Antoine F Carpentier, Elie Azoulay, Catherine Thieblemont, Roberta Di Blasi, Sophie Caillat-Zucman
Journal: Journal for ImmunoTherapy of Cancer (2024)

Immune effector cell-associated neurotoxicity syndrome (ICANS) remains a significant cause of morbidity associated with CD19-targeted chimeric antigen receptor (CAR) T-cell therapy. Early prediction of patients who will develop ICANS would be crucial to better guide individualized management of high-risk patients, but specific predictive markers are still missing. Serum neurofilament light chain (NfL) levels are a sensitive indicator of neuroaxonal injury in neurological diseases. Elevated NfL levels at the time of CAR T-cell infusion have been associated with the severity of ICANS, but their utility for earlier identification of patients with subclinical neurological damage has not been evaluated. We studied all consecutive adult patients who received commercial CAR T cells for relapsed/refractory B-cell lymphomas at Saint-Louis Hospital between January 2019 and February 2023. Patients with pre-existing or current neurological disease were excluded. NfL levels were quantified in frozen serum collected at the time of the decision to treat (ie, the day of leukapheresis) and at the time of treatment (ie, the day of infusion). Of the 150 study patients, 28% developed ICANS of any grade, including 15.3% of grade 2–4. Receiving a CAR construct with a CD28 domain (58% of patients) was the strongest predictor of grade 2–4 ICANS. Serum NfL levels were significantly higher in patients with grade 2–4 ICANS than in those with grade 0–1 ICANS, both at the time of leukapheresis and infusion. In multivariate models, NfL above the cut-off value was independently associated with grade 2–4 ICANS at leukapheresis (NfL&gt;75 pg/mL, OR 4.2, 95% CI 1.2 to 14.2, p=0.022) and infusion (NfL&gt;58 pg/mL, OR 4.3, 95% CI 1.3 to 13.7, p=0.015). In conclusion, high NfL levels at the time of the decision to proceed with CAR T-cell manufacturing may represent an early surrogate of underlying loss of neuroaxonal integrity that increases the risk of subsequent neurotoxicity. Incorporating NfL levels into the decision-making process based on each patient’s risk profile could help determine the appropriate CAR product when possible, and guide the prophylactic or therapeutic management of ICANS.
Systemic juvenile idiopathic arthritis and adult-onset Still’s disease are the same disease: evidence from systematic reviews and meta-analyses informing the 2023 EULAR/PReS recommendations for the diagnosis and management of Still’s disease
Authors: Arianna De Matteis, Sara Bindoli, Fabrizio De Benedetti, Loreto Carmona, Bruno Fautrel, Stéphane Mitrovic
Journal: Annals of the Rheumatic Diseases (2024)

Objectives To analyse the similarity in clinical manifestations and laboratory findings between systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease (AOSD). Methods Three systematic reviews (SR) were performed. One included cohort studies comparing sJIA versus AOSD that described clinical and biological manifestations with at least 20 patients in each group (SR1). The second identified studies of biomarkers in both diseases and their diagnostic performance (SR2). The last focused on diagnostic biomarkers for macrophage activation syndrome (MAS, SR3). Medline (PubMed), Embase and Cochrane Library were systematically searched. The risk of bias was assessed with an adapted form of the Hoy scale for prevalence studies in SR1 and the Quality Assessment of Diagnostic Accuracy Studies-2 in SR2 and SR3. We performed meta-analyses of proportions for the qualitative descriptors. Results Eight studies were included in SR1 (n=1010 participants), 33 in SR2 and 10 in SR3. The pooled prevalence of clinical manifestations did not differ between sJIA and AOSD, except for myalgia, sore throat and weight loss, which were more frequent in AOSD than sJIA because they are likely ascertained incompletely in sJIA, especially in young children. Except for AA amyloidosis, more frequent in sJIA than AOSD, the prevalence of complications did not differ, nor did the prevalence of biological findings. Ferritin, S100 proteins and interleukin-18 (IL-18) were the most frequently used diagnostic biomarkers, with similar diagnostic performance. For MAS diagnosis, novel biomarkers such as IL-18, C-X-C motif ligand 9, adenosine deaminase 2 activity and activated T cells seemed promising. Conclusion Our results argue for a continuum between sJIA and AOSD. PROSPERO registration number CRD42022374240 and CRD42024534021.
Clinical information on imaging referrals for suspected or known axial spondyloarthritis: recommendations from the Assessment of Spondyloarthritis International Society (ASAS)
Authors: Torsten Diekhoff, Chiara Giraudo, Pedro M Machado, Michael Mallinson, Iris Eshed, Hildrun Haibel, Kay Geert Hermann, Manouk de Hooge, Lennart Jans, Anne Grethe Jurik, Robert Gw Lambert, Walter Maksymowych, Helena Marzo-Ortega, Victoria Navarro-Compán, Mikkel Østergaard, Susanne Juhl Pedersen, Monique Reijnierse, Martin Rudwaleit, Fernando A Sommerfleck, Ulrich Weber, Xenofon Baraliakos, Denis Poddubnyy
Journal: Annals of the Rheumatic Diseases (2024)

Objectives This study aims to establish expert consensus recommendations for clinical information on imaging requests in suspected/known axial spondyloarthritis (axSpA), focusing on enhancing diagnostic clarity and patient care through guidelines. Materials and methods A specialised task force was formed, comprising 7 radiologists, 11 rheumatologists from the Assessment of Spondyloarthritis International Society (ASAS) and a patient representative. Using the Delphi method, two rounds of surveys were conducted among ASAS members. These surveys aimed to identify critical elements for imaging referrals and to refine these elements for practical application. The task force deliberated on the survey outcomes and proposed a set of recommendations, which were then presented to the ASAS community for a decisive vote. Results The collaborative effort resulted in a set of six detailed recommendations for clinicians involved in requesting imaging for patients with suspected or known axSpA. These recommendations cover crucial areas, including clinical features indicative of axSpA, clinical features, mechanical factors, past imaging data, potential contraindications for specific imaging modalities or contrast media and detailed reasons for the examination, including differential diagnoses. Garnering support from 73% of voting ASAS members, these recommendations represent a consensus on optimising imaging request protocols in axSpA. Conclusion The ASAS recommendations offer comprehensive guidance for rheumatologists in requesting imaging for axSpA, aiming to standardise requesting practices. By improving the precision and relevance of imaging requests, these guidelines should enhance the clinical impact of radiology reports, facilitate accurate diagnosis and consequently improve the management of patients with axSpA.
Guselkumab in Behçet’s disease
Authors: Elie E Ghayad, Georgina Maalouf, Arsène Mekinian, Giacomo Emmi, Matheus Vieira, Adrien Mirouse, Anne-Claire Desbois, Alexandre Le Joncour, Fanny Domont, Gaëlle Leroux, Helene Bugaut, Mathieu Vautier, Patrice Cacoub, Stéphane Barete, David Saadoun
Journal: Annals of the Rheumatic Diseases (2024)